Journal
NUCLEIC ACIDS RESEARCH
Volume 46, Issue 4, Pages 1895-1911Publisher
OXFORD UNIV PRESS
DOI: 10.1093/nar/gkx1306
Keywords
-
Categories
Funding
- National Institutes of Health [CA134514, CA130908, CA193239]
- Department of Defense [W81XWH-14-1-0486, W81XWH-15-1-0634]
- National Natural Science Foundation of China [31501052]
- Mayo Clinic Center for Individualized Medicine [MC1351]
- Minnesota Partnership for Biotechnology and Medical Genomics [MNP] [14.37]
- Prostate Cancer Foundation (Prostate Cancer Foundation Challenge Award)
- Mayo Clinic Schulze Cancer for Novel Therapeutics in Cancer Research
- Mayo Clinic Cancer Center
- Pharmacogenomics Research Network (PGRN)
- Janssen Research & Development, LLC
Ask authors/readers for more resources
Androgen receptor (AR) splice variants (ARVs) are implicated in development of castration-resistant prostate cancer (CRPC). Upregulation of ARVs often correlates with persistent AR activity after androgen deprivation therapy (ADT). However, the genomic and epigenomic characteristics of ARV-dependent cistrome and the disease relevance of ARV-mediated transcriptome remain elusive. Through integrated chromatin immunoprecipitation coupled sequencing (ChIP-seq) and RNA sequencing (RNA-seq) analysis, we identified ARV-preferential-binding sites (ARV-PBS) and a set of genes preferentially transactivated by ARVs in CRPC cells. ARVs preferentially bind to enhancers located in nucleosome-depleted regions harboring the full AR-response element (AREfull), while full-length AR (ARFL)-PBS are enhancers resided in closed chromatin regions containing the composite FOXA1-nnnn-AREhalf motif. ARV-PBS exclusively overlapped with AR binding sites in castration-resistant (CR) tumors in patients and ARV-preferentially activated genes were up-regulated in abiraterone-resistant patient specimens. Expression of ARV-PBS target genes, such as oncogene RAP2A and cell cycle gene E2F7, were significantly associated with castration resistance, poor survival and tumor progression. We uncover distinct genomic and epigenomic features of ARV-PBS, highlighting that ARVs are useful tools to depict AR-regulated oncogenic genome and epigenome landscapes in prostate cancer. Our data also suggest that the ARV-preferentially activated transcriptional program could be targeted for effective treatment of CRPC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available